Health Canada, the Canadian government’s public health department, has initiated a safety review of the diabetes drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors and their link to ketoacidosis. Ketoacidosis is a serious blood condition wherein the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can cause death.
Last month, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication warning of a link between the SGLT2 ...
continue reading...
